Randomized clinical trials are valuable in determining the effectiveness of health treatments. But problems with design, execution or reporting of the trial process can lead to unreliable findings, excessive costs, and, potentially, harm for patients. Associate Professor Halil Kilicoglu and his colleagues seek to address this problem with the help of a $1,328,502 grant from the National Institutes of Health.